6van Ruth S,Mathot RA,Sparidans RW,et al.Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.Clin Pharmacokinet,2004,43(2):131-143.
7Ikeguchi M, Oka A, Tsjuitani S, etal. Relationship between area of sera invasion and intraperitoneal free cancer cells inpatients with gastric cancer. Anticancer Res, 1994, 14:2131-2134.
8S ugarbaker PH. Adjuvant intraperitoneal chemotherapy for ad-vanced primary gastric cancer [J]. Scand J Surg,2006,95(4):270 -273.
9Di Miceli D,Alfieri S,Caprino P,et al. Complications related to hy-perthermia during hypertermic intraoperative intraperitoneal chemi-otherapy (HIPEC) treatment. Do they exist [ J] . Eur Rev MedPharmacol Sci, 2012,16(6) :737 -742.
10Emoto S,Ishigami H,Hidemura A,et al. Complications and man-agement of an implanted intraperitoneal access port system for in-traperitoneal chemotherapy for gastric cancer with peritoneal metas-tasis[j]. Jpn J Clin Oncol, 2012,18(7) :810-814.
